{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056507","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.244805+00:00","generated_at":"2026-06-28T09:25:43.042307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ALX Oncology Q3 net loss $24.6M; cash $385M; acquired ScalmiBio","bullets":["GAAP net loss $24.6M ($0.61/sh) vs $10.8M ($0.36/sh) in Q3 2020; non-GAAP loss $20.4M.","R&D expenses $18.2M, up from $5.3M, driven by higher clinical costs and stock-based comp.","Cash and equivalents $385.1M; runway projected through 2024.","Acquired ScalmiBio Oct 2021 for ~$4.5M upfront + $2M milestone and royalties; gains SHIELD ADC platform.","Dosed first patients in ASPEN-05 (AML) and Zymeworks combo trial; ASH/SITC data presented or pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056507","json":"https://secwatch.observer/filing/0001564590-21-056507.json","markdown":"https://secwatch.observer/filing/0001564590-21-056507.md","text":"https://secwatch.observer/filing/0001564590-21-056507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000156459021056507/0001564590-21-056507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000156459021056507/alxo-8k_20211111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:25:43.042307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}